《盈警响号》金斯瑞生物科技(01548.HK)料中期亏损扩大至最多1.77亿美元
金斯瑞生物科技(01548.HK)发盈警,料中期将录得1.53亿美元至1.77亿美元亏损,较去年同期之3,330万美元扩大。
公司表示,除传奇生物科技以外,公司非细胞疗法业务的利润料约为1,610万美元至1,880万美元。对传奇的投资、即细胞疗法业务之持续运营料将录得8,900万美至1.03亿美元亏损,其中不计入包括发行A类可转换可赎回优先股的佣金、有关优先股的公允价值变动,及上市费用造成的一次性费用。亏损中包括研发费用9,650万美元至1.12亿美元。另外,期内因A类可转换可赎回优先股公允价值变动导致8,000万美元之一次性非现金费用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.